

## Recent applications of isatin in the synthesis of organic compounds

Razieh Moradi,<sup>a</sup> Ghodsi Mohammadi Ziarani,<sup>\*a</sup> and Negar Lashgari<sup>b</sup>

<sup>a</sup> Department of Chemistry, Alzahra University, Tehran, Iran

<sup>b</sup> School of Chemistry, College of Science, University of Tehran, Tehran, Iran

E-mail: [gmziarani@hotmail.com](mailto:gmziarani@hotmail.com) [gmohammadi@alzahra.ac.ir](mailto:gmohammadi@alzahra.ac.ir)


Received 12-06-2016

Accepted 02-25-2017

Published on line 04-10-2017

### Abstract

Isatin has been used in design and synthesis of diverse types of heterocyclic and carbocyclic compounds and considered as a valuable building block in organic synthesis. There is a diversity of multicomponent reactions of this useful reagent. This article aims to review the advances in the use of isatin as starting material in the synthesis of various organic compounds and drugs up to June 2016.



**Keywords:** Isatin, organic compounds, heterocyclic compounds, carbocyclic compounds

## Table of Contents

1. Introduction
  2. Reactions at the C-3 Position of Isatin
  3. Synthesis of Isatin-based Spiro-fused Heterocyclic Frameworks
    - 3.1 Synthesis involving two-component reactions of isatins
      - 3.1.1 Three-membered heterocycles
      - 3.1.2 Five-membered heterocycles
      - 3.1.3 Six-membered heterocycles
      - 3.1.4 Seven-membered heterocycles
  4. Synthesis Involving Multicomponent Reactions
    - 4.1 Three-membered heterocycles
    - 4.2 Five-membered heterocycles
    - 4.3 Six-membered heterocycles
    - 4.4 Seven-membered heterocycles
  5. Synthesis of Isatin-based Spiro-fused Carbocyclic Frameworks
  6. Miscellaneous Reactions
  7. Conclusions
- Acknowledgements
- Abbreviations
- References

## 1. Introduction


Isatin was first obtained by Erdmann<sup>1</sup> and Laurent<sup>2</sup> in 1840 as a product of the oxidation of indigo dye by nitric acid and chromic acid. Isatin is one of the most important heterocyclic compounds. For example, Schiff bases of isatin are used for their pharmaceutical properties.<sup>3</sup> Oxindole as an isatin derivative represents an important class of heterocyclic compounds endowed of interesting pharmacological<sup>4,5</sup> and biological activities such as antimicrobial,<sup>6</sup> antitumor,<sup>7,8</sup> antitubercular,<sup>9,10</sup> antimalaria,<sup>11</sup> anti-HIV<sup>12</sup> and antibacterial activities.<sup>13</sup> On the other hand, the chiral 3,3-disubstituted oxindole framework is a privileged motif found in various natural products and pharmaceutically active compounds.<sup>14</sup> As a class of important 3,3-disubstituted oxindoles, 3-substituted 3-hydroxyindolin-2-ones have attracted considerable attention because of their diverse biological activities.<sup>15,16</sup>

During recent years several review articles were published on isatins. Singh and Desta reviewed isatin as a privileged molecule in design and synthesis of spiro-fused cyclic frameworks.<sup>17</sup> Synthesis of spiro<sup>18</sup> and multispiro<sup>19</sup> heterocyclic compounds from isatin were studied by Borad et al. The enantioselective reactions of isatin were also the subject of several review articles.<sup>20-22</sup> Herein, in continuation of our studies towards isatin,<sup>23-25</sup> and since there is a wide range of reactions that include isatin in the synthesis of organic compounds, this review presents the recent applications of isatin in the synthesis of different types of organic compounds up to June 2016.

## 2. Reactions at the C-3 Position of Isatin


The direct asymmetric aldol reaction between isatin derivatives **1** and acetone **2** at -35 °C in EtOH using *N*-

arylprolinamides has been developed and the corresponding aldol products **3** were obtained (Scheme 1).<sup>26</sup> The same authors used trans-4-hydroxy-L-prolinamide as a catalyst in this reaction.<sup>27</sup> In a similar reaction,  $\alpha$ -cross-coupling aldol addition of activated olefins **4** with isatins **1** has been described in the presence of ruthenium(III) chloride and tributyltin hydride (TBTH) at room temperature to afford 3-substituted-3-hydroxy-2-oxindoles **5** (Scheme 1).<sup>28</sup>




Scheme 1

The vinylation of isatins **1** by vinyl boronic acids **6** catalyzed by  $\text{CoBr}_2$  in the presence of DuanPhos was reported for the synthesis of the tertiary allylic alcohols **7** (Scheme 2).<sup>29</sup>




Scheme 2




The alkynylation reaction of isatins **1** and aryl-substituted alkynes **8** in the presence of bifunctional guanidine/ $\text{CuI}$  as catalyst was accomplished for the synthesis of 3-substituted 3-hydroxyoxindole scaffolds **9** (Scheme 3).<sup>30</sup> In another study, zinc dust was also used as catalyst in this reaction.<sup>31</sup>




$\text{R}^1$  = H, 4-Cl, 5-F, 5-Br, 5-I, 5-MeOO, 5-CF<sub>3</sub>O,  
 7-F, 7-Br, 7-Cl, 7-I, 7-CF<sub>3</sub>, 7-CF<sub>3</sub>O  
 $\text{R}^2$  = 2-FC<sub>6</sub>H<sub>4</sub>, 3-FC<sub>6</sub>H<sub>4</sub>, 4-FC<sub>6</sub>H<sub>4</sub>, 3-ClC<sub>6</sub>H<sub>4</sub>,  
 3-MeC<sub>6</sub>H<sub>4</sub>, 4-MeC<sub>6</sub>H<sub>4</sub>, 3-MeOC<sub>6</sub>H<sub>4</sub>,  
 CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>, CH<sub>2</sub>OCOEt, CH<sub>2</sub>OCOPh, CH<sub>2</sub>O<sup>t</sup>Bu,  
 CH<sub>2</sub>NHBoc, <sup>i</sup>Pr, cyclopropyl, <sup>n</sup>C<sub>5</sub>H<sub>11</sub>, <sup>n</sup>C<sub>10</sub>H<sub>21</sub>,  
 cyclopentyl, cyclohexyl, propenyl, octynyl,  
 2-methylisoindolinyl-1,3-dione



Scheme 3




$\text{R}^1$  = H  
 $\text{R}^2$  = H, 5-Me, 5-MeO, 5-F, 5-Cl,  
 5,7-Me<sub>2</sub>, 4,6-Br<sub>2</sub>, 6-Br, 7-Me,  
 7-Cl, 6,7-Me<sub>2</sub>, 6-Cl-7-Me  
 $\text{R}^3$  = H, Me, CH<sub>2</sub>OAc



Scheme 4

The diastereoselective total synthesis of leucolusine **16** was described by the coupling of enantioenriched (*R*)-1-benzyl-3-(2-bromoethyl)-3-((*tert*-butyldimethylsilyl)oxy)indolin-2-one **13** with **14**, which gave **15** in 57% yield (Scheme 4).<sup>32</sup> Precursor **13** was prepared from **12** that obtained from 3-alkyl-3-hydroxyindolin-2-one **11** by the known organocatalytic cross-aldol reaction between acetaldehyde **10** and *N*-benzylisatin **1**. Global deprotection of **15** using *t*BuLi/O<sub>2</sub> in THF at -78 °C followed by treatment with TBAF led to the formation of natural leucolusine **16** with 68% isolated yield. In another study, the 3-allyl-3-hydroxyoxindoles **18** were obtained from allylation reaction of isatin derivatives **1** and allyltrimethylsilane **17** using the (*S*)-difluorophos derived chiral Hg(OTf)<sub>2</sub> complex as a catalyst (Scheme 4).<sup>33</sup>


The diastereo- and enantio-selective aldol addition of allenic esters **19** to isatins **1** in the presence of AuCl<sub>3</sub> and chiral *N,N'*-dioxide has been reported for the synthesis of the carbinol allenates **20** (Scheme 5).<sup>34</sup> The decrease in yield and enantioselectivity was mainly due to the steric hindrance of vicinal 4-substituted bulky halogen atoms (4-Cl, 4-Br). 5,7-Dimethyl-substituted isatin provided the best enantioselectivity.




Scheme 5

A series of 3-hydroxy-7-aza-2-oxindoles **23** have been synthesized in good yields and moderate to high enantioselectivity via the enantioselective Morita–Baylis–Hillman (MBH) reaction of 7-azaisatins **21** with maleimides **22** in the presence of bifunctional tertiary amine, β-isocupreidine (β-ICD) as the catalyst (Scheme 6).<sup>35</sup>

Shankaraiah's group designed the synthesis of new (*Z*)-3-(3'-methoxy-4'-(2-amino-2-oxoethoxy)benzylidene)indolin-2-one derivatives **25** from the Knoevenagel condensation reaction of isatin derivatives **1** and 3-methoxy-4-(2-amino-2-oxoethoxy)-benzaldehydes **24** (Scheme 7).<sup>36</sup> The products were evaluated for their cytotoxic activity against selected human cancer cell lines of prostate (PC-3 and DU-145), breast (BT-549 and MDA-MB-231) and non-tumorigenic prostate epithelial cells (RWPE-1).




Scheme 6




Scheme 7

Shaker and Marzouk investigated the condensation of isatin **1** with acetohydrazide **26** to yield the oxoindolinylidene **27** (Scheme 8).<sup>37</sup> The newly prepared compound was tested *in vitro* against a panel of four human tumor cell lines, namely hepatocellular carcinoma (liver) HePG-2, colon cancer HCT-116, human prostate cancer PC3, and mammary gland breast MCF-7. It was also tested as an antioxidant.




Scheme 8

Terada's group developed a methodology based on the two-step sequence strategy for the synthesis of 3-arylisatin derivatives **30** from the isatin derivatives **1** and aryl boron salts **29**. The methodology involves the formation of an oxindole having a phosphate moiety **28** at the C-3 position via the [1,2]-phospha-Brook rearrangement under Brønsted base catalysis and the subsequent palladium-catalyzed cross-coupling reaction with aryl boron **29** reagents (Scheme 9).<sup>38</sup>




Scheme 9

Bajaj and co-workers reported the use of macrocyclic Ti(IV)-salen complexes as catalysts for enantioselective hydrophosphonylation (EHP) reaction of isatin derived ketimines **31** with diphenyl phosphate **32** as nucleophile. The corresponding phosphonylated products **33** were obtained in high enantioselectivity (ee up to 99%) (Scheme 10).<sup>39</sup>




Scheme 10

In another study, Su and Xu developed the synthesis of optically pure 2-oxoindoliny- $\beta^{3,3}$ -amino esters **36** in good yields via the diastereoselective asymmetric Reformatsky-type reaction of isatin-derived chiral *N*-sulfinyl ketimines **34** with ethyl bromoacetate **35** (Scheme 11).<sup>40</sup>



Scheme 11


Kureshy's group synthesized the  $\beta$ -nitro amines **38** from the asymmetric aza-Henry reaction of various isatin derived *N*-Boc ketimines **31** with nitromethanes **37** in the presence of the chiral Cu(II) dimeric macrocyclic salen complex as catalyst (ee, up to 99%). This protocol was also used for the synthesis of enantiomerically pure (*S*)- $\beta$ -diamines **39** via asymmetric aza-Henry reaction of *N*-Boc ketimine **31** in two steps in good yield and high enantioselectivity (Scheme 12).<sup>41</sup>




Scheme 12



Pedro's group reported the enantioselective addition of 4-substituted pyrazolones **40** to isatin-derived ketimines **31**. In this study, the authors used a bifunctional organocatalyst (a quinine-derived thiourea) to provide a variety of chiral heterocyclic compounds containing both aminooxindole and pyrazolone moieties bearing vicinal quaternary stereocenters **41** (Scheme 13).<sup>42,43</sup>




Scheme 13



Scheme 14

Various  $\alpha$ -allylated 3-amino-2-oxindoles **43a** were achieved by the Barbier-type allylation of isatin imines **31** with allylic compounds **42a** using metallic barium as the promoter (Scheme 14).<sup>44</sup> In a similar study, Chen and Cai described the  $\text{In}(\text{OTf})_3$ -catalyzed allylation of ketimines derived from isatins **31** in the presence of an imidazolypyridine ligand, **L** (Scheme 14).<sup>45</sup>

The 2-oxindoles bearing chiral  $\alpha$ -tertiary amines at the 3-position **46** were prepared in good yields and with high enantioselectivities via a  $\text{Pd}(\text{II})/\text{Pyrox}$ -catalyzed addition of arylboronic acids **45** to 3-ketimine isatins **44** (Scheme 15).<sup>46</sup> The absolute configuration of one of the products ( $\text{R}^2 = \text{H}$ ) was determined to be *R* and the absolute configuration of the  $\text{C}=\text{N}$  bond of the 3-ketimine isatin was determined to be *E* by X-ray crystallographic analysis.






**Scheme 15**


A simple and efficient way for the synthesis of a series of chiral  $\alpha$ -trifluoromethylamines **49** with excellent yields and stereoselectivities was reported by Li and co-workers. The reaction was performed between *N*-2,2,2-trifluoroethylisatin ketimines **47** and MBH type carbonates **48** using  $\beta$ -isocupreidine ( $\beta$ -ICD) as catalyst. A possible mechanism of this reaction was proposed, as shown in scheme 16,  $\beta$ -ICD attacks the MBH carbonate **48** via an  $\text{S}_{\text{N}}2'$  process (intermediate **B**). It behaves as a Lewis base chiral catalyst. This is followed by another  $\text{S}_{\text{N}}2'$ -type process, with the isatinketimine **47** acting as an active nucleophile (intermediate **A**) (Scheme 16).<sup>47</sup>

Elghamry and Al-Faiyz developed a new method for the synthesis of quinoline-4-carboxylic acids **51** using isatin **1** and enaminones **50** as a substitute for 1,3-dicarbonyl compounds in the Pfitzinger reaction (Scheme 17).<sup>48</sup>

Microwave assisted synthesis of 4-phenyl-1,3-thiazole derivatives **54** from the reaction of isatin **1**, 2-bromoethanones **52** and thiosemicarbazide **53** has been accomplished (Scheme 18).<sup>49</sup> The synthesized compounds were tested for their antimicrobial activities.




2,4-Dinitrophenol (DNP) facilitated the three component reaction of isatins **1**, cyclic-amines **55** and alkynes **8** to prepare the mono-functionalized  $\alpha$ -alkynyl-3-amino-2-oxindole derivatives **56** (Scheme 19).<sup>50</sup>



Scheme 19


The new indole derivative 5,5''-difluoro-1*H*,1''*H*-[3,3':3',3''-terindol]-2'-(1'*H*)-one **58** has been synthesized from the reaction of isatin **1** and 2 eq. 5-fluoroindole **57** in the presence of sulfamic acid as an efficient organocatalyst (Scheme 20).<sup>51</sup> Crystal structure of the product was determined by X-ray structure analysis. In other studies, the reactions of various isatin derivatives **1** and indoles **57** were also investigated in the presence of nano SiO<sub>2</sub><sup>52</sup> and Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub>@SO<sub>3</sub>H<sup>53</sup> as catalysts.




Scheme 20

A tunable copper-catalyzed azide-alkyne cycloaddition (CuAAC)-initiated multicomponent reaction strategy for the construction of 3-functionalized indolin-2-ones have been reported. In this regard, the reaction of isatins **1**, tosyl azides **59**, and terminal alkynes **8** in the presence of CuI and Et<sub>4</sub>Nl was developed. This tandem process can be manipulated to proceed in three-component and four-component fashion respectively, yielding a range of (*Z*)-3-alkenyloxindole **60** or 3-substituted 3-hydroxyoxindole **61** compounds (Scheme 21).<sup>54</sup>

Meshram and co-workers reported a one-pot four component protocol for the synthesis of a novel class of functionalized (*Z*)-5-(3-hydroxy-2-oxindolin-3-yl)-2-iminothiazolidin-4-ones **63** by the reaction of substituted isatins **1**, amines **55**, phenylisothiocyanate **62** and ethyl bromoacetate **35** in the presence of DABCO as catalyst in aqueous medium (Scheme 22).<sup>55</sup> The 5-halo isatins reacted under standard condition and resulted in moderate yields of products while other 5-substituted isatins reacted smoothly to furnish the desired products in high yields. As like monosubstituted isatins, disubstituted isatins reacted in the same way and afforded comparatively less yield of desired products under standard reaction conditions.



Scheme 21



Scheme 22

### 3. Synthesis of Isatin-based Spiro-fused Heterocyclic Frameworks

The heterocyclic spirooxindole ring system is a widely distributed structural framework in a number of pharmaceuticals and natural products,<sup>56</sup> including cytostatic alkaloids such as spirotryprostatins A, B, and strychnophylline.<sup>57</sup> The unique structural array and the highly pronounced pharmacological activity displayed by the class of spirooxindole compounds have made them attractive synthetic targets (Figure 1).<sup>58-60</sup>





Figure 1


### 3.1. Synthesis involving two-component reactions of isatins

**3.1.1. Three-membered heterocycles.** Hajra *et al.* carried out the asymmetric synthesis of spiroaziridine oxindoles **67a**, **67b** via the aza Corey-Chaykovsky reaction of isatin-derived tert-butanefulfonyl ketimines **64** with *in situ* generated sulfur ylide from trimethylsulfonium iodide **65** (or the reaction of benzyl sulfur ylides generated from *S*-benzyl tetrahydrothiophenium bromide **66** with chiral tertbutanesulfonyl ketimines **64**) and NaH (Scheme 23).<sup>61</sup>




Scheme 23

An efficient chemoselective access to rare spiro-epoxyoxindoles **70** has been developed through the addition of the carbenoid chloromethyl lithium **69** to various *N*-functionalized isatins **1** followed by the ring closure (Scheme 24).<sup>62</sup>




Scheme 24

**3.1.2. Five-membered heterocycles.** Wang *et al.* developed an  $\alpha$ -regioselective asymmetric [3 + 2] annulation reaction of isatins **71** and 1-azadienes **72** for the synthesis of bulky 1,2-benzisothiazole 1,1-dioxide motifs **73** (Scheme 25).<sup>63</sup>




Scheme 25

Zhao and Du developed an efficient cascade Michael/Michael reaction catalyzed by a bifunctional tertiary amine–squaramide catalyst for the asymmetric synthesis of five-membered spirooxindoles containing five contiguous stereocenters **76** from the reaction of isatin derived enoates **74** and  $\alpha$ -alkylidene succinimides **75**. The products were obtained with excellent diastereoselectivities and enantioselectivities (Scheme 26).<sup>64</sup>



Scheme 26


The functionalized 3,3'-pyrrolidinyldispirooxindole derivatives **78** with three stereogenic centers, including two contiguous spiro-stereocenters were achieved from the stereoselective organocatalytic Mannich/Boc-deprotection/aza-Michael sequence reaction of isatin imines **31** and the 3-substituted oxindoles **77** employing the commercially available (DHQD)<sub>2</sub>PHAL as the catalyst (Scheme 27).<sup>65</sup>



Scheme 27


The synthesis of 3,2'-dihydropyrrolyl spirooxindoles **80** with excellent enantioselectivities (up to >99%) was accomplished by asymmetric [3 + 2] annulation of isatin imines **31** with zwitterions generated from allenyl esters as well as allenyl ketones **79** catalyzed by L-isoleucine derived bifunctional *N*-acylaminophosphine (Scheme 28).<sup>66</sup>






Scheme 28

The enantioenriched spirooxindole based 4-thiazolidinones **82** were accessed through the catalytic asymmetric [3 + 2] annulation of isatin ketimines **31** with the 1,4-dithiane-2,5-diol **81** using a bifunctional catalyst followed by simple oxidation with high enantioselectivity (up to 98% ee) (Scheme 29).<sup>67</sup>




Scheme 29

**3.1.3. Six-membered heterocycles.** The hetero-Diels–Alder (hDA) reaction of isatins **1** with enones **83** that was catalyzed by an amine-based catalyst system composed of three molecules (an amine, an acid and a thiourea) was accomplished for synthesis of the functionalized spirooxindole tetrahydropyran derivatives **84** according to intermediates **A-C** (Scheme 30).<sup>68,69</sup>



### Scheme 30


The enantioselective [4 + 2] assemble of spirolactones **85** through a chiral *N*-heterocyclic carbene (NHC)-catalyzed remote  $\gamma$ -carbon addition of enals **83** with isatins **1** was reported by Zhou and co-workers (Scheme 31).<sup>70</sup> Yao and co-workers studied this reaction using the same catalyst and base.<sup>71</sup>



### Scheme 31


The vinylogous aldol-cyclization cascade reaction of 3-alkylidene oxindoles **86** to isatins **1** has been achieved by using bifunctional organocatalysts in CH<sub>2</sub>Cl<sub>2</sub> at room temperature. According to the proposed

mechanism, first oxindole **87** was deprotonated by catalyst and generated *s-cis* enolate **A**, which then was added through the *Si* face to isatin **1** to give alkoxide intermediate **B**. After cyclization and protonation of the intermediate **B**, the desired product **87** was delivered and catalyst was regenerated (Scheme 32).<sup>72</sup>



Scheme 32


The biologically active dihydropyrones **89** with a high level of enantioselectivities were synthesized from the hetero-Diels–Alder reaction of isatins **1** and glyoxal **88** in the presence of chiral copper catalyst (Scheme 33).<sup>73</sup>



Scheme 33


The synthesis of 1-*H*-spiro[isindoline-1,2'-quinazoline]-3,4'(3'*H*)-diones **91** has been expediently accomplished by a reaction of isatins **1** and anthranilamide **90** in the presence of sulfamic acid as an efficient

catalyst (Scheme 34).<sup>74</sup> The products were found to be fluorescent with absorption in UV region (302, 362 nm) and emission in visible region (413-436 nm) with Stokes shift of 44-72 nm.




Scheme 34

Kumarswamyreddy and Kesavan used the bifunctional squaramide organocatalyst derived from L-proline in the reaction between isatylidene  $\beta,\gamma$ -unsaturated  $\alpha$ -ketoesters **92** and pyrazolones **40** for the synthesis of dihydrospiro[indoline-3,4'-pyrano[2,3-c]pyrazole] derivatives **93** (Scheme 35).<sup>75</sup>




Scheme 35

An enantioselective Michael–Michael cascade reaction for the synthesis of chiral spiro-tetrahydrothiopyrans **95** was studied by Wang *et al.* In this reaction, highly functionalized scaffolds were assembled via the reaction of chiral spiro-tetrahydrothiopyranoxindoles **94** with *trans*-enones **83** using the organocatalyst in excellent diastereo- and enantio-selectivities (>30:1 dr,  $\geq 99\%$  ee) with the creation of four consecutive stereogenic centers. The novel spiro-oxindole scaffolds were validated as a new class of p53-MDM2 protein-protein interaction inhibitors with good antitumor activity (Scheme 36).<sup>76</sup>





Scheme 36

Kumar *et al.* reported the synthesis of 1,3-dihydro-3-ureidoformimido-2*H*-indol-2-ones **97** and spiro[3*H*-indole-3,2'(1'*H*)-(1,3,5)triazine]-2,4',6'(1*H*,3'*H*,5'*H*)-triones **98** from the reaction of isatins **1** and biuret **96** (Scheme 37).<sup>77</sup> The reactions were carried out in two different methods; method A under slightly acidic conditions and method B in the presence of glacial acetic acid as reaction medium. It was observed that under both conditions compound **97** was obtained as the main product, however method B also resulted in the formation of compound **98** as a minor product.



Scheme 37

**3.1.4. Seven- membered heterocycles.** The quaternary aza-spirocycloheptane oxindole scaffolds **100** have been synthesized via the [4 + 3] cycloaddition reaction of MBH carbonates derived from isatin **71** and *N*-(*o*-chloromethyl)aryl amides **99** catalyzed by Lewis base and Brønsted base (Scheme 38). According to the proposed mechanism, the nucleophilic reaction of Bu<sub>3</sub>P with MBH carbonate affords intermediate **A** with the concurrent release of CO<sub>2</sub>. The *in situ* generated *tert*-butoxide anion then deprotonates intermediate **A** to yield the allylic phosphonium ylids **B**. Intermediate **D** is obtained by a  $\gamma$ -regioselective Michael type addition between allylic phosphonium ylide **B** and aza-*o*-quinone methide **C** generated *in situ* through the Cs<sub>2</sub>CO<sub>3</sub>-mediated elimination of **99**. Finally, intermediate **D** undergoes an intramolecular cyclization process to afford the desired product **100** with the regeneration of Bu<sub>3</sub>P (Scheme 38).<sup>78</sup>




Scheme 38

## 4. Synthesis Involving Multicomponent Reactions

Reactions involving more than two components are usually referred to as multicomponent reactions (MCRs). Multicomponent reactions have emerged as powerful synthetic strategies because of their efficiency, atom economy, high selectivity and convenient construction of multiple new bonds.<sup>79-81</sup> These characteristics give rapid access to combinatorial libraries of complex organic molecules for efficient lead structure identification and optimization in drug discovery.<sup>82-84</sup> This section reviews three-, four and five-component reactions of isatins that have been employed in the synthesis of three- to seven membered spiro-heterocycles bearing one or more heteroatoms.

### 4.1. Three-membered heterocycles


The three-component reaction of isatins **1**, *N*-substituted aziridine **101** and 2-(trimethylsilyl)aryl triflate **102** was carried out for the synthesis of trisubstituted *N*-aryl  $\alpha$ -amino epoxides **103** (Scheme 39).<sup>85</sup>



Scheme 39

#### 4.2. Five-membered heterocycles


Kumar and co-workers reported the microwave-assisted three-component 1,3-dipolar cycloaddition reaction of isatin **1**, 1-allyl-3,5-bis(4-methoxyphenylmethylidene)piperidin-4-one **104** and thioproline **105** for the regioselective synthesis of dispiro oxindole-pyrrolothiazole-piperidones **106** (Scheme 40).<sup>86</sup>




Scheme 40

Liu *et al.* developed a method for the synthesis of isoxazole-fused spiropyrrolidine oxindoles **110-112** via a 1,3-dipolar cycloaddition reaction of azomethine ylides (thermally generated *in situ* from isatin **1** derivatives and proline **107**/ thioproline **105**/ sarcosine **108**) with 3-methyl-4-nitro-5-alkenyl-isoxazoles **109** (Scheme 41).<sup>87</sup> The products showed considerable cytotoxicities against human prostate cancer cells PC-3, human lung cancer cells A549 and human leukemia cells K562.

The multicomponent 1,3-dipolar cycloaddition reaction of azomethine ylides (generated *in situ* from isatin derivatives **1** and sarcosine **108**) with dienones **113** was carried out and novel turmerone motif fused spiropyrrolidine oxindoles **114** were obtained in high yields and good diastereoselectivity (up to >20:1) (Scheme 42).<sup>88</sup> The biological activity test results demonstrated that most of the compounds showed considerable cytotoxicities to cell lines of K562 and A549, showed comparably potent or even more potent than the positive control of cisplatin (up to 5.1 times).




Scheme 41



Scheme 42


Novel spiro-tethered pyrazolo[3,4-*b*]quinoline hybrids **117-119** from the reaction of isatin **1**,  $\alpha$ -amino acids (**108**, **105**, **116**) and 6-arylidene-pyrazolo[3,4-*b*]quinolin-5-ones **115**, have been synthesized (Scheme 43).<sup>89</sup>






Scheme 43

A series of novel functionalized dispirooxindoles **121**, **122** have been synthesized through 1,3-dipolar cycloaddition of an azomethine ylide formed from isatins **1** and various amino acids such as sarcosine **108** and proline **107** with 4-arylmethylene-2-pyrrolin-5-one **120** under microwave irradiation conditions (Scheme 44).<sup>90</sup>




Scheme 44

The spirooxindole-pyrrolidine/piperidine fused nitrochromanes **124** were synthesized via cycloaddition reaction of isatin **1**, proline **107** and nitrochromene **123** (Scheme 45).<sup>91</sup> The regio- and stereo-chemical results were ascertained by X-ray crystallographic study.




Scheme 45

The indole-based compounds **126** were obtained through the multi-component reaction of azomethine ylides (generated through condensation of isatins **1** with sarcosine **108**) with 1-alkyl-3,5-bis(arylidene)-4-piperidones **125** (Scheme 46).<sup>92</sup> X-ray studies of products provided good support for the regio- and stereoselectivity of the reaction. Many of the synthesized spiro-indoles exhibit antitumor properties against HeLa (cervical cancer) cell line.




Scheme 46

The regio- and stereoselective fashion three-component 1,3-dipolar cycloaddition of azomethine ylides generated *in situ* from the condensation of isatins **1** and secondary amino acids (sarcosine **108**/L-thioproline **105**) with 3-arylidene-thiochroman-4-ones **127** resulted in the formation of a series of novel dispiro compounds containing oxindole pyrrolidine/oxindolopyrrolthiazole-thiochroman-4-one hybrid frameworks **128, 129** (Scheme 47).<sup>93</sup>



Scheme 47


Mohan's group described the synthesis of new and highly functionalized regio- and stereoselective bisoxindole-containing dispiropyrrolidinyl/thiapyrrolizidinyl hybrid molecules **131**, **132** obtained through 1,3-dipolar cycloaddition reactions of azomethines (generated *in situ* from isatin **1** and sarcosine **108** or thioproline **105**) with (*E*)-3-((2-methoxyquinolin-3-yl)-methylene)indolin-2-one dipolarophiles **130** (Scheme 48).<sup>94</sup> All synthesized compounds were evaluated for their *in vitro* antioxidant activities.



Scheme 48


Hamama *et al.* described the azomethine cycloaddition reactions to the synthesis of dispiro[indoline-3,2'-pyrrolidine-3',3'-quinoline] **134** using isatin **1**, sarcosine **108**, and  $\alpha,\beta$ -unsaturated ketone **133** (Scheme 49). From the calculations using frontier orbital theory, the authors found that the *endo* cycloaddition intermediate has a binding energy with 42.9 Kcal/mol more negative value than the *exo* cycloaddition intermediate.

Because the benzene ring of arylidene and the benzene ring of azomethine ylid are parallel to each other, the *endo* cycloaddition intermediate is more stable than the *exo* cycloaddition intermediate, and the dispiro *endo*-cycloaddition is formed while the dispiro *exo*-cycloaddition product is not formed by exocycloaddition (Scheme 49).<sup>95</sup>




Scheme 49

The reaction of (2*E*,4*E*)-ethyl 5-(phenylsulfonyl)penta-2,4-dienoate **135** as a dipolarophile with *in situ* generated azomethine ylides from isatin **1** and sarcosine **108** derivatives in refluxing 1,4-dioxane furnished the cycloadducts **136** in good yields (Scheme 50).<sup>96</sup>




Scheme 50

Through the reaction of isatin derivatives **1**, benzyl amines **55** and (Z)-3-(2-oxo-2-phenylethylidene)indolin-2-one **137** using ceric ammonium nitrate (CAN), the functionalized spirooxindole-pyrrolidines **138** were synthesized (Scheme 51).<sup>97</sup> All the synthesized products showed good antimicrobial activity.



Scheme 51


Spiro[indoline-3,2'-pyrrole] derivatives were obtained from the reaction of isatins **1**,  $\alpha$ -amino acids **108** and phenylpropionic acid esters **139** in refluxing isopropanol in high regioselectivity and yields. A plausible mechanism for this multicomponent reaction was proposed (Scheme 52).<sup>98</sup> First, the condensation of isatin **1** with sarcosine **108** afforded the corresponding azomethine ylide **A**. Subsequently, the protic solvent of isopropanol would promote the decarboxylation of azomethine ylide **A** to form the 1,3-dipole **B**. Then, the 1,3-dipolar cycloaddition of intermediate **B** with methyl 3-phenylpropiolate **139** results in the final product spiro[indoline-3,2'-pyrrole] **140**.



Scheme 52


Shi and co-workers developed an asymmetric chemoselective 1,3-dipolar cycloaddition of azomethine ylide with imines via the three component reaction of isatin-derived imines **31**, aldehydes **11** and amino-ester

**141** in the presence of chiral phosphoric acid. In this reaction, spiro[imidazolidine-2,3'-oxindole] frameworks **142** were obtained with high diastereo and enantioselectivities (97 : 3 er, all >95:5 dr) (Scheme 53).<sup>99</sup>




Scheme 53

Safaei-Ghomi and Zahedi reported application of  $\text{Fe}_3\text{O}_4$ -L-proline NPs as a chiral catalyst to achieve high diastereoselectivities in the asymmetric 1,3-dipolar cycloaddition reaction of isatins **1**, *N*-arylhydroxylamines **143** and enones **83** for the synthesis of spiroisoxazolidines **144** (Scheme 54).<sup>100</sup>




Scheme 54

DBSA (*p*-dodecylbenzenesulfonic acid) as an efficient Brønsted acid surfactant combined catalyst facilitated the reaction of isatin derivatives **1** with primary amines **55** and thioglycolic acid **145** for the synthesis of a series of pharmacologically important spiro[indoline-3,2'-thiazolidinones] **146**, **147**. First, a reaction of isatin **1** and amines **55** was carried out to generate the corresponding Schiff base intermediate **A** and **B** which after the addition of thioglycolic acid in the same flask afforded the desired product (Scheme 55).<sup>101</sup>




Scheme 55

Rajeswari *et al.* employed a one-pot four-component [3 + 2] cycloaddition process using *N*-propargylated isatin **1**, coumarin-3-carboxylic acid **147**, *L*-proline **107**/sarcosine **108** and aryl azides **148** with Cu as a catalyst to prepare the selective spirooxindole pyrrolizine linked 1,2,3-triazole conjugates **149**, **150** (Scheme 56).<sup>102</sup>




Scheme 56

Meshram's group have demonstrated an efficient and regioselective synthesis of spirooxindoles **153** from the reaction of isatins **1**,  $\beta$ -nitrostyrenes **151** and benzylamine **55**/ $\alpha$ -amino acids **152** under microwave irradiation (Scheme 57).<sup>103</sup> All products were screened for antimicrobial activity and the majority of compounds showed significant activities.



Scheme 57


Khurana's group reported the synthesis of novel heterocyclic triazolyl spirocyclic oxindoles **155** via the one-pot five component reaction of isatin **1**, 1,3-dicarbonyl **154**, aryl azides **148**, aromatic aldehydes **11**, and L-proline **107** using DBU as a catalyst in PEG-400 (Scheme 58).<sup>104</sup>



Scheme 58

#### 4.3. Six-membered heterocycles


The spiro-dihydropyridine derivatives **158** were synthesized via a one-pot multicomponent condensation of isatin derivatives **1** and malononitrile **156** with ketene amins **157** under catalyst-free conditions in PEG-400 as a highly efficient and green biodegradable polymeric medium (Scheme 59).<sup>105</sup> All compounds showed moderate to high level activity against acetyl and butyrylcholinesterase.



Scheme 59




Spirooxindoles incorporating a "medicinally privileged" indenopyridine moiety **161** have been synthesized regioselectively via multicomponent reaction of isatins **1**, 1,1-dicyanomethylene-3-indanone **159** and malononitrile **156** in the presence of amines **160** (Scheme 60).<sup>106</sup> The product is a spirooxindole-fused indenopyridine salt that was successfully neutralized by dilute hydrochloric acid.




Scheme 60

Treatment of isatin derivatives **1** and barbituric acids **162** with 6-amino-1,3-dimethyl uracil **163** using SBA-15-Pr-SO<sub>3</sub>H as a heterogeneous nano catalyst in one pot reaction, resulted in the formation of the spirooxindole dipyrimidine derivatives **164** in high yields (Scheme 61).<sup>107</sup>




Scheme 61

In another study, Mohammadi Ziarani and co-workers reported a method for the synthesis of spiro indeno[1,2-*b*]pyrido[2,3-*d*]pyrimidine-5,3'-indolines **166** through the condensation reaction of isatins **1**, 6-aminouracil **163** and 1,3-indanedione **165** in the presence of SBA-15-Pr-SO<sub>3</sub>H as a heterogeneous nano catalyst (Scheme 62).<sup>108</sup> The same authors also reported microwave irradiation condition for this reaction.<sup>109</sup>




Scheme 62

Siddiqui's group prepared the pyrazolo-pyridopyrimidines **169** by the four-component reaction of isatins **1**, 6-amino-1-methyluracil **163**,  $\beta$ -ketoester **167** and hydrazines **168** in the presence of a catalytic amount of iodine (Scheme 63).<sup>110</sup>




Scheme 63

An efficient methodology for the synthesis of substituted spiro[indolo-3,10'-indeno[1,2-*b*]quinoline]-2,4,11'-triones **170** by the reaction of isatins **1**, 1,3-indanedione **165**, and enaminones **50** using  $\text{La}(\text{OTf})_3$  as catalyst in PEG-400 under conventional heating and or ultrasonic irradiation was reported by Kumari *et al.* (Scheme 64).<sup>111</sup>




Scheme 64

Thanikachalam and co-workers prepared a spirooxindole compound namely 2'-amino-6'-(1*H*-indol-3-yl)-2-oxospiro[indole-3,4'-pyran]-3',5'-dicarbonitrile **172**, from the reaction of isatin **1**, 2-cyanoacetylindole **171** and malononitrile **156** (Scheme 65).<sup>112</sup>




Scheme 65

The one-pot three-component condensation of isatins **1**,  $\alpha$  or  $\beta$ -naphthols **173**, **174**, and cyclic 1,3-dicarbonyl compounds **154** in the presence of Fe<sub>3</sub>O<sub>4</sub>@MCM-41-SO<sub>3</sub>H@[HMIIm][HSO<sub>4</sub>] as catalyst was successfully established for the synthesis of new derivatives of spiro[benzoxanthene-indoline]diones **175** (Scheme 66).<sup>113</sup>



Scheme 66


Shi and Yan reported a method for the synthesis of functionalized spiro[indoline-3,4'-pyrano[3,2-*h*]quinolines] **178** via the three-component condensation of isatins **1**, 8-hydroxyquinoline **176** and malononitrile **156** or ethyl cyanoacetate **177** (Scheme 67).<sup>114</sup>



Scheme 67


A dicationic ionic liquid (IL) and K<sub>2</sub>CO<sub>3</sub> were used as an efficient catalytic system for the synthesis of 4*H*-pyrans **179** via the three-component condensation reaction of isatin derivatives **1**, malononitrile **156**, and 1,3-dicarbonyl compounds **154** in water (Scheme 68).<sup>115</sup> This reaction has been widely studied and different

catalysts such as [Amb]*L*-proline,<sup>116</sup> tetrabutylammonium bromide (TBAB),<sup>117</sup> boron nitride supported iron oxide (BN@Fe<sub>3</sub>O<sub>4</sub>),<sup>118</sup> Al-ITQ-HB,<sup>119</sup> [bmim]OH,<sup>120</sup> Fe<sub>3</sub>O<sub>4</sub>,<sup>121</sup> carbon nanotube (CNT),<sup>122</sup> NaOAc,<sup>123</sup> CuFe<sub>2</sub>O<sub>4</sub> nanoparticles<sup>124</sup> and trisodium citrate dihydrate<sup>125</sup> were used in this reaction.




Scheme 68

The preparation of spiropyran derivatives **180** using silica-bonded 1,4-diazabicyclo[2.2.2]octane-sulfonic acid chloride (SBDBSAC) as a catalyst in multicomponent reaction of isatin derivatives **1**, barbituric acids **162**, and 1,3-dicarbonyl compounds **154** was reported by Moosavi-Zare and co-workers (Scheme 69).<sup>126</sup>




Scheme 69

The synthesis of chiral, enantioenriched spiro(indoline-pyrimidine)-dione derivatives **182** from the asymmetric, Biginelli-like reaction of *N*-substituted isatins **1**, urea **181** and β-ketoesters **167** using BINOL-derived phosphoric acid as a catalyst has been studied by Stocchi *et al.* (Scheme 70).<sup>127</sup>




### Scheme 70

A variety of spirooxindole derivatives **184** were synthesized by a facile one pot, three-component protocol using isatin **1**, isatoic anhydride **183** and amines **55** in the presence of CuO–Pd nanoparticles as catalyst. The nucleophilic addition of aniline **55** to isatoic anhydride **183**, in the presence of the CuO–Pd NPs, followed by decarboxylation, produced 2-aminobenzamide **A**. The condensation of **A** with isatin **1**, in the presence of CuO–Pd NPs, gave imine **B**, which on intramolecular cyclization gave the final product **184** (Scheme 71).<sup>128</sup>




### Scheme 71

Pardasani and co-workers studied a novel three-component reaction for the synthesis of spiro-benzimidazoquinazolinones **186** via the reaction of isatins **1**, dimedone **154** and 2-aminobenzimidazole **185** under microwave irradiation (Scheme 72).<sup>129</sup> This one-pot process involves the formation of one C–C and two C–N bonds during the synthesis of the spiro-compounds as confirmed by X-ray analysis.




Scheme 72

Alizadeh and Moafi developed a three-component domino reaction of isatin derivatives **1**, 2-aryl-2-oxoethyl thiocyanates **187** and hydrazonoyl chlorides **188** that provides a convenient method for the synthesis of 4'-H-spiro[indole-3,5'-[1,3,4]thiadiazin]-2(1H)-ones **189** (Scheme 73).<sup>130</sup>




Scheme 73

Novel steroidal dihydropyridinyl spirooxindoles **192** were synthesized by the multicomponent reaction of isatins **1**, pregnenolone (PREG) **190**, malononitrile **156** and ammonium acetate **191** (Scheme 74).<sup>131</sup> MTT assay indicated that some of these compounds exhibited moderate to excellent cytotoxic activity against the tested cancer cell lines. The cytotoxic activities varied greatly depending on the position and electronic nature of substituents on the isatin nucleus and *N*-benzyl moieties.



### Scheme 74


Rajanarendar *et al.* used *p*-toluene sulfonic acid (*p*-TSA) as an efficient catalyst in the reaction of isatin derivatives **1**, 1,3-indanedione **165** and 4-amino-3-methyl-5-styrylisoxazole **193** for the synthesis of isoxazolyldiindeno[1,2-*b*;2',1'-*e*]pyridine-11,3'-indoline-2',10,12-triones **194** (Scheme 75).<sup>132</sup>




### Scheme 75

Oxalic acid dihydrate: proline (LTTM) promoted the synthesis of spiro[diindeno[1,2-*b*;2',1'-*e*]pyridine-11,3'-indoline]-triones **195** in the reaction of isatins **1**, 1,3-indanedione **165** and anilines **55** as starting materials (Scheme 76).<sup>133</sup>

Shaabani *et al.* studied the synthesis of fully substituted naphthyridines **199** through the domino reaction of isatin derivatives **1**, diamines **196**, 1,1-bis(methylthio)-2-nitroethylene **197** and 2-aminoprop-1-ene-1,1,3-tricarbonitrile **198** using a deep eutectic solvent (DES) (Scheme 77).<sup>134</sup>




Scheme 76



Scheme 77


Shrestha *et al.* reported a one-pot synthesis of biologically spiro[indoline-3,4'-pyrano[2,3-c]pyrazole] derivatives **200** using  $\text{CeO}_2$  nanoparticle-catalyzed four-component reaction of isatins **1**,  $\beta$ -ketoesters **167**, phenylhydrazines **168** and malononitrile **156** in water (Scheme 78).<sup>135</sup> In another study,  $\text{Fe}_3\text{O}_4@\text{SiO}_2$  was used as the catalyst of this reaction.<sup>136</sup>



Scheme 78




The synthesis of 2-hydroxy-3-[(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1*H*-pyrazol-4-yl)(phenyl)methyl]-naphthalene-1,4-dione derivatives **202** has been developed through a one-pot, four-component reaction of isatin **1**, 2-hydroxy-1,4-naphthoquinone **201**, hydrazine **168** and  $\beta$ -ketoester **167** catalyzed by  $\text{MgCl}_2$  in ethylene glycol (Scheme 79).<sup>137</sup>



Scheme 79

#### 4.4. Seven-membered heterocycles

Condensation of isatin **1** with a C,N-1,6-binucleophile generated *in situ* from *o*-aminobenzaldehyde **11** and 2-methylindole **57** through a Mannich-type reaction was established for the synthesis of a quinoline-fused 1-benzazepine derivative **203** (Scheme 80).<sup>138</sup>




Scheme 80

### 5. Synthesis of Isatin-based Spiro-fused Carbocyclic Frameworks


Zhan *et al.* investigated the asymmetric annulation reactions of Morita–Baylis–Hillman carbonates, derived from isatins **71** and 2-alkylidene-1*H*-indene-1,3(2*H*)-diones **165**, catalyzed by various chiral Lewis bases, which resulted in a switch in chemo- and diastereoselectivity. While [2 + 1] reactions catalyzed by chiral tertiary amines, derived from cinchona alkaloids, produced densely substituted cyclopropanes **204**, diastereodivergent

[3 + 2] annulations generated bis(spirocycl)ic oxindoles **205** by employing either a chiral phosphine or a DMAP-type catalyst (Scheme 81).<sup>139</sup>




Scheme 81

Pepsin was used as a biocatalyst in the domino Knoevenagel/Michael/Michael reaction for the synthesis of spirooxindole derivatives in methanol. A wide range of isatins **1** and enones **83** in reaction with malononitrile **156** provided spirocyclic oxindoles **206** in yields of up to 99% and oxindoles **207** in trace yields with diastereoselectivity up to >99:1 dr (Scheme 82).<sup>140</sup> Reactions with isatins bearing an electron-donating group in the 5-position gave better yields than those bearing a strong electron-withdrawing group in the 5-position. The position of substituents also had effects on the reaction yield. The isatins with a substituent in the 5-position gave higher yields than those with a substituent in the 1- or 7-position.



Scheme 82


Hegade and co-workers developed an organocatalyzed pseudo four-component reaction of isatin derivatives **1**, cyclohexanone **208**, and malononitrile **156** in the presence of a catalytic amount of DABCO for the synthesis of functionalized spirooxindoles **209** (Scheme 83).<sup>141</sup>



Scheme 83

## 6. Miscellaneous Reactions


From the reaction of isatin **1** and thiosemicarbazide **53** through multiple steps (involving the intermediates **A-E**) a series of semicarbazones containing 1,3,4-thiadiazino and indole rings **210** were synthesized (Scheme 84).<sup>142</sup> All the newly synthesized compounds were investigated for anticonvulsant activity.



Scheme 84


A unique two-carbon ring expansion of isatins **1** has been achieved to conveniently construct the functionalized dibenzo[*b,d*]azepin-6-one scaffolds **212** while one carbon atom is from the *N*-substituent of

pyridinium bromide **211** and the other is from indene-1,3-dione **165**. The possible reaction mechanism for two-carbon ring expansion has been shown in scheme 85. Pyridinium bromide **211** was first deprotonated to a pyridinium ylide under the basic conditions. The Michael addition of pyridinium ylide to the condensation product **A** resulted in the formation of zwitterion **B** without other regio-isomers, and this might have resulted from the more electron-deficient 3-position on the isatin **1** than the 2-position of indan-1,3-dione **165**. The following proton transfer gave a new zwitterion **C**, and the intramolecular nucleophilic addition of the carbon anion to the 2-carbonyl group of the isatinyl moiety afforded a cyclopropyl intermediate **D**. The less strong electron-withdrawing nature of  $R^2$  groups such as *p*-nitrobenzyl makes this transfer hard to occur, and this multi-component reaction stops at this stage. The re-opening of cyclopropane oxide **D** leads to the attack of the newly generated carbon anion on the carbonyl group in the indene-1,3-dione **165**. The resulting cyclopropyl oxide **E** further re-opened and the removal of pyridine afforded cyclopropane **F**. The following cyclopropane reorganized to the ring-expanded product **212** (Scheme 85).<sup>143</sup>



Scheme 85

The spiro[pyrrolo-4,10'-indeno[1,2-*b*]quinolin]-3-carboxylate compounds **213** were obtained from the reaction of isatin derivatives **1**, amines **55**,  $\beta$ -ketoesters **167** and indane-1,3-dione **165** with activated alumina balls (3–5 mm diameter) as a catalyst under neat reaction conditions (Scheme 86).<sup>144</sup> Except for *n*-butylamine (which resulted in lower yields), the products were obtained in good to excellent yields (72–92%) whether there is an electron-donating or –withdrawing substituent on the aromatic ring. The substituted isatin derivatives with Cl and Br at the 5-position also reacted efficiently to give high yields.



Scheme 86

## 7. Conclusions

Isatin is one of the important heterocyclic structures with special significance for the synthesis of organic compounds. Schiff bases of isatin, 3,3-disubstituted oxindoles and spirooxindoles are some important structures that can be synthesized using isatin as an starting material. More importantly, most of these compounds exhibit biological and pharmaceutical activities. In recent years, isatin has been widely used in the synthesis of a variety of organic compounds. Due to the widespread use of isatin in organic reactions and pursuant to our previous studies, herein we have an overview of recent applications of isatin in the synthesis of organic compounds up to June 2016.

## Acknowledgements

We are grateful for financial support from the Research Council of Alzahra University.

## Abbreviations

DABCO: diazabicyclooctane

DBU: diazabicycloundecene

DCE: dichloroethane

DCM: dichloromethane

DMF: dimethylformamide

EG: ethylene glycol

MTBE: methyl tertiary-butyl ether

PEG: polyethylene glycol

TBAF: tetrabutylammonium fluoride

TBSOTf: tert-butyldimethylsilyl trifluoromethanesulfonate

TFA: trifluoroacetic acid

THF: tetrahydrofuran

## References

1. Erdmann, O. L. J. *Prakt. Chem.* **1840**, 19, 321.  
<http://dx.doi.org/10.1002/ardp.18400720604>
2. Laurent, A. *Ann. Chim. Phys.* **1840**, 3, 393.
3. Jarrahpour, A. A.; Khalili, D. *Molbank* **2005**, 4, M437.  
<http://dx.doi.org/10.3390/M437>
4. Fortt, R.; Smith, G.; Awais, R. O.; Luthra, S. K.; Aboagye, E. O. *Nucl. Med. Biol.* **2012**, 39, 1000.  
<http://dx.doi.org/10.1016/j.nucmedbio.2012.03.004>
5. Ermut, G.; Karal, N.; Cetin, I.; Topcul, M.; Birteksoz, S. *Marmara Pharm. J.* **2013**, 17, 147.  
<http://dx.doi.org/10.12991/201317383>
6. Kumar, M.; Ramasamy, K.; Mani, V.; Mishra, R. K.; Majeed, A. B. A.; Clercq, E. D.; Narasimhan, B. *Arabian J. Chem.* **2014**, 7, 396.  
<http://dx.doi.org/10.1016/j.arabjc.2012.12.005>
7. Havrylyuk, D.; Zimenkovsky, B.; Vasylenko, O.; Gzella, A.; Lesyk, R. *J. Med. Chem.* **2012**, 55, 8630.  
<http://dx.doi.org/10.1021/jm300789g>
8. Kumar, S. B.; Ravinder, M.; Kishore, G.; Rao, V. J.; Yogeeswari, P.; Sriram, D. *Med. Chem. Res.* **2014**, 23, 1934.  
<http://dx.doi.org/10.1007/s00044-013-0787-x>
9. Kumar, K.; Kremer, S. C.; Kremer, L.; Gueerardel, Y.; Biot, C.; Kumar, V. *Organomet.* **2013**, 32, 5713.  
<http://dx.doi.org/10.1021/om301157z>
10. Mondal, P.; Jana, S.; Balaji, A.; Ramakrishna, R.; Kanthal, L. *J. Young Pharm.* **2013**, 4, 38.  
<http://dx.doi.org/10.4103/0975-1483.93574>
11. Raj, R.; Singh, P.; Singh, P.; Gut, J.; Rosenthal, P. J.; Kumar, V. *Eur. J. Med. Chem.* **2013**, 62, 590.  
<http://dx.doi.org/10.1016/j.ejmech.2013.01.032>
12. Paul, B. K.; Ray, D.; Guchhait, N. *Phys. Chem. Chem. Phys.* **2013**, 15, 1275.  
<http://dx.doi.org/10.1039/C2CP42539D>
13. Kiran, G.; Maneshwar, T.; Rajeshwar, Y.; Sarangapani, M. *J. Chem.* **2013**, 2013, 1.  
<http://dx.doi.org/10.1155/2013/192039>
14. Zhou, F.; Liu, Y.-L.; Zhou, J. *Adv. Synth. Catal.* **2010**, 352, 1381.  
<http://dx.doi.org/10.1002/adsc.201000161>
15. Peddibhotla, S. *Curr. Bioact. Compd.* **2009**, 5, 20.  
<http://dx.doi.org/10.2174/157340709787580900>
16. Badillo, J. J.; Hanhan, N. V.; Franz, A. K. *Curr. Opin. Drug Discovery Dev.* **2010**, 13, 758.
17. Singh, G. S.; Desta, Z. Y. *Chem. Rev.* **2012**, 112, 6104.  
<http://dx.doi.org/10.1021/cr300135y>
18. Borad, M. A.; Bhoi, M. N.; Prajapati, N. P.; Patel, H. D. *Synth. Commun.* **2014**, 44, 897.  
<http://dx.doi.org/10.1080/00397911.2013.843196>

19. Borad, M. A.; Bhoi, M. N.; Prajapati, N. P.; Patel, H. D. *Synth. Commun.* **2014**, *44*, 1043.  
<http://dx.doi.org/10.1080/00397911.2013.858361>
20. Ball-Jones, N. R.; Badillo, J. J.; Franz, A. K. *Org. Biomol. Chem.* **2012**, *10*, 5165.  
<http://dx.doi.org/10.1039/C2OB25184A>
21. Flores, M.; Pena, J.; García, P. G.; Garrido, N. M.; Díez, D. *Curr. Org. Chem.* **2013**, *17*, 1957.  
<http://dx.doi.org/10.2174/13852728113179990092>
22. Liu, Y.; Wang, H.; Wan, J. *Asian J. Org. Chem.* **2013**, *2*, 374.  
<http://dx.doi.org/10.1002/ajoc.201200180>
23. Mohammadi Ziarani, G.; Moradi, R.; Lashgari, N. *Arkivoc* **2016**, (i), 1.  
<http://dx.doi.org/10.3998/ark.5550190.p009.385>
24. Lashgari, N.; Mohammadi Ziarani, G. *Arkivoc* **2012**, (i), 277.  
<http://dx.doi.org/10.3998/ark.5550190.0013.108>
25. Mohammadi Ziarani, G.; Moradi, R.; Lashgari, N. *Tetrahedron: Asymmetry* **2015**, *26*, 517.  
<http://dx.doi.org/10.1016/j.tetasy.2015.04.011>
26. Yadav, G. D.; Singh, S. *Tetrahedron: Asymmetry* **2016**, *27*, 123.  
<http://dx.doi.org/10.1016/j.tetasy.2015.12.005>
27. Yadav, G. D.; Singh, S. *Tetrahedron: Asymmetry* **2016**, *27*, 463.  
<http://dx.doi.org/10.1016/j.tetasy.2016.04.008>
28. Sanjeeva Kumar, A.; Santosh Kumar, G.; Babu Nanubolu, J. *RSC Adv.* **2016**, *6*, 1705.  
<http://dx.doi.org/10.1039/C5RA14714J>
29. Huang, Y.; Huang, R.-Z.; Zhao, Y. *J. Am. Chem. Soc.* **2016**, *138*, 6571.  
<http://dx.doi.org/10.1021/jacs.6b02372>
30. Chen, Q.; Tang, Y.; Huang, T.; Liu, X.; Lin, L.; Feng, X. *Angew. Chem., Int. Ed.* **2016**, *55*, 5286.  
<http://dx.doi.org/10.1002/anie.201600711>
31. Singh, V. K.; Upadhyay, A.; Singh, R. K. P. *Tetrahedron Lett.* **2017**, *58*, 156.  
<http://dx.doi.org/10.1016/j.tetlet.2016.11.124c>
32. Pandey, G.; Khamrai, J. *Asian J. Chem.* **2016**, *5*, 621.  
<http://dx.doi.org/10.1002/ajoc.201600101>
33. Xu, N.; Gu, D.-W.; Zi, J.; Wu, X.-Y.; Guo, X.-X. *Org. Lett.* **2016**, *18*, 2439.  
<http://dx.doi.org/10.1021/acs.orglett.6b00971>
34. Wang, G.; Liu, X.; Chen, Y.; Yang, J.; Li, J.; Lin, L.; Feng, X. *ACS Catal.* **2016**, *6*, 2482.  
<http://dx.doi.org/10.1021/acscatal.6b00294>
35. He, Q.; Zhan, G.; Du, W.; Chen, Y. C. *Beilstein J. Org. Chem.* **2016**, *12*, 309.  
<http://dx.doi.org/10.3762/bjoc.12.33>
36. Senwar, K. R.; Reddy, T. S.; Thummuri, D.; Sharma, P.; Naidu, V. G. M.; Srinivasulu, G.; Shankaraiah, N. *Eur. J. Med. Chem.* **2016**, *118*, 34.  
<http://dx.doi.org/10.1016/j.ejmech.2016.04.025>
37. Shaker, S. A.; Marzouk, M. I. *Molecules* **2016**, *21*, 155.  
<http://dx.doi.org/10.3390/molecules21020155>
38. Kondoh, A.; Takei, A.; Terada, M. *Synlett* **2016**, *27*, 1848.  
<http://dx.doi.org/10.1055/s-0035-1561859>
39. Nazish, M.; Jakhar, A.; Noor-ul, H. K.; Verma, S.; Kureshy, R. I.; Abdi, S. H.; Bajaj, H. C. *Appl. Catal., A* **2016**, *515*, 116.

- <http://dx.doi.org/10.1016/j.apcata.2015.12.037>
40. Su, L.; Xu, M.-H. *Synthesis* **2016**, 48, 2595.  
<http://dx.doi.org/10.1055/s-0035-1561426>
41. Menapara, T.; Choudhary, M. K.; Tak, R.; Kureshy, R. I.; Noor-ul, H. K.; Abdi, S. H. *J. Mol. Catal. A: Chem.* **2016**, 421, 161.  
<http://dx.doi.org/10.1016/j.molcata.2016.05.021>
42. Amr, F. I.; Vila, C.; Blay, G.; Muñoz, M. C.; Pedro, J. R. *Adv. Synth. Catal.* **2016**, 358, 1583.  
<http://dx.doi.org/10.1002/adsc.201600036>
43. Vila, C.; Amr, F. I.; Blay, G.; Muñoz, M. C.; Pedro, J. R. *Chem. Asian J.* **2016**, 11, 1532.  
<http://dx.doi.org/10.1002/asia.201600325>
44. Yanagisawa, A.; Yamafuji, S.; Sawae, T. *Synlett* **2016**, 27, 2019.  
<http://dx.doi.org/10.1055/s-0035-1561450>
45. Chen, T.; Cai, C. *Org. Biomol. Chem.* **2016**, 14, 5019.  
<http://dx.doi.org/10.1039/C6OB00551A>
46. He, Q.; Wu, L.; Kou, X.; Butt, N.; Yang, G.; Zhang, W. *Org. Lett.* **2016**, 18, 288.  
<http://dx.doi.org/10.1021/acs.orglett.5b03458>
47. Li, X.; Su, J.; Liu, Z.; Zhu, Y.; Dong, Z.; Qiu, S.; Wang, J.; Lin, L.; Shen, Z.; Yan, W. *Org. Lett.* **2016**, 18, 956.  
<http://dx.doi.org/10.1021/acs.orglett.5b03566>
48. Elghamry, I.; Al-Faiyz, Y. *Tetrahedron Lett.* **2016**, 57, 110.  
<http://dx.doi.org/10.1016/j.tetlet.2015.11.070>
49. Yogi, P.; Ashid, M.; Hussain, N.; Khan, S.; Joshi, A. *Asian J. Chem.* **2016**, 28, 927.  
<http://dx.doi.org/10.14233/ajchem.2016.19603>
50. Kumar, M.; Kaur, B. P.; Chimni, S. S. *Chem. Eur. J.* **2016**, 22, 9948.  
<http://dx.doi.org/10.1002/chem.201601222>
51. Sharma, S.; Banerjee, B.; Brahmachari, G.; Kant, R.; Gupta, V. K. *Crystallogr. Rep.* **2016**, 61, 225.  
<http://dx.doi.org/10.1107/S2052520616005060>
52. Nikoofar, K.; Khalili, Z. Z. *Naturforsch. B Chem. Sci.* **2016**, 71, 31.  
<http://dx.doi.org/10.1515/znbs-2015-0111>
53. Hassani, H.; Nasser, M. A.; Zakerinasab, B.; Rafiee, F. *Appl. Organomet. Chem.* **2016**, 30, 408.  
<http://dx.doi.org/10.1002/aoc.3447>
54. Cheng, D.; Ling, F.; Zheng, C.; Ma, C. *Org. Lett.* **2016**, 18, 2435.  
<http://dx.doi.org/10.1021/acs.orglett.6b00964>
55. Bejjam, M. B.; Kumar, G. S.; Swetha, A.; Meshram, H. *RSC Adv.* **2016**, 6, 13820.  
<http://dx.doi.org/10.1039/C5RA24127H>
56. Williams, R. M.; Cox, R. J. *Acc. Chem. Res.* **2003**, 36, 127.  
<http://dx.doi.org/10.1021/ar020229e>
57. Cui, C.-B.; Kakeya, H.; Osada, H. *J. Antibiot.* **1996**, 49, 832.  
<http://dx.doi.org/10.7164/antibiotics.49.832>
58. Fischer, C.; Meyers, C.; Carreira, E. M. *Helv. Chim. Acta* **2000**, 83, 1175.  
[http://dx.doi.org/10.1002/1522-2675\(20000607\)83:6<1175::AID-HLCA1175>3.0.CO;2-D](http://dx.doi.org/10.1002/1522-2675(20000607)83:6<1175::AID-HLCA1175>3.0.CO;2-D)
59. Alper, P. B.; Meyers, C.; Lerchner, A.; Siegel, D. R.; Carreira, E. M. *Angew. Chem., Int. Ed.* **1999**, 38, 3186.  
[http://dx.doi.org/10.1002/\(SICI\)1521-3773\(19991102\)38:21<3186::AID-ANIE3186>3.0.CO;2-E](http://dx.doi.org/10.1002/(SICI)1521-3773(19991102)38:21<3186::AID-ANIE3186>3.0.CO;2-E)
60. Ashimori, A.; Bachand, B.; Overman, L. E.; Poon, D. J. *J. Am. Chem. Soc.* **1998**, 120, 6477.



- <http://dx.doi.org/10.1021/ja980786p>
61. Hajra, S.; Aziz, S. M.; Jana, B.; Mahish, P.; Das, D. *Org. Lett.* **2016**, *18*, 532.  
<http://dx.doi.org/10.1021/acs.orglett.5b03564>
62. Pace, V.; Castoldi, L.; Mamuye, A. D.; Langer, T.; Holzer, W. *Adv. Synth. Catal.* **2016**, *358*, 172.  
<http://dx.doi.org/10.1002/adsc.201500840>
63. Wang, K.-K.; Jin, T.; Huang, X.; Ouyang, Q.; Du, W.; Chen, Y.-C. *Org. Lett.* **2016**, *18*, 872.  
<http://dx.doi.org/10.1021/acs.orglett.6b00189>
64. Zhao, B.-L.; Du, D.-M. *Chem. Commun.* **2016**, *52*, 6162.  
<http://dx.doi.org/10.1039/C6CC00705H>
65. Zhao, K.; Zhi, Y.; Li, X.; Puttreddy, R.; Rissanen, K.; Enders, D. *Chem. Commun.* **2016**, *52*, 2249.  
<http://dx.doi.org/10.1039/C5CC10057G>
66. Kumar, K.; Sankar, M. G.; Garcia-Castro, M.; Golz, C.; Strohman, C. *RSC Adv.* **2016**, *6*, 56537.  
<http://dx.doi.org/10.1039/C6RA12387B>
67. Cheng, P.; Guo, W.; Chen, P.; Liu, Y.; Du, X.; Li, C. *Chem. Commun.* **2016**, *52*, 3418.  
<http://dx.doi.org/10.1039/C5CC10292H>
68. Cui, H.-L.; Chouthaiwale, P. V.; Yin, F.; Tanaka, F. *Org. Biomol. Chem.* **2016**, *14*, 1777.  
<http://dx.doi.org/10.1039/C5OB02393A>
69. Cui, H. L.; Chouthaiwale, P. V.; Yin, F.; Tanaka, F. *Asian J. Org. Chem.* **2016**, *5*, 153.  
<http://dx.doi.org/10.1002/ajoc.201500412>
70. Rong, X.; Yao, H.; Xia, W.; Du, Y.; Zhou, Y.; Liu, H. *ACS Comb. Sci.* **2016**, *18*, 220.  
<http://dx.doi.org/10.1021/acscombsci.5b00197>
71. Zhu, L.; Yu, C.; Li, T.; Wang, Y.; Lu, Y.; Wang, W.; Yao, C. *Org. Biomol. Chem.* **2016**, *14*, 1485.  
<http://dx.doi.org/10.1039/C5OB02160J>
72. Han, J. L.; Chang, C. H. *Chem. Commun.* **2016**, *52*, 2322.  
<http://dx.doi.org/10.1039/C5CC08883F>
73. Li, Y.; Hu, Y.; Zhang, S.; Sun, J.; Li, L.; Zha, Z.; Wang, Z. *J. Org. Chem.* **2016**, *81*, 2993.  
<http://dx.doi.org/10.1021/acs.joc.5b02780>
74. Mane, M. M.; Pore, D. M. *J. Chem. Sci.* **2016**, *128*, 657.  
<http://dx.doi.org/10.1007/s12039-016-1047-7>
75. Kumarswamyreddy, N.; Kesavan, V. *Org. Lett.* **2016**, *18*, 1354.  
<http://dx.doi.org/10.1021/acs.orglett.6b00287>
76. Wang, S.; Jiang, Y.; Wu, S.; Dong, G.; Miao, Z.; Zhang, W.; Sheng, C. *Org. Lett.* **2016**, *18*, 1028.  
<http://dx.doi.org/10.1021/acs.orglett.6b00155>
77. Kumar, D.; Sharma, L. K.; Sharma, K.; Jain, R. *J. Heterocycl. Chem.* **2017**, *54*, 570.  
<http://dx.doi.org/10.1002/jhet.2623>
78. Liu, J.-Y.; Lu, H.; Li, C.-G.; Liang, Y.-M.; Xu, P.-F. *Synlett* **2016**, *27*, 1287.  
<http://dx.doi.org/10.1055/s-0035-1560600>
79. Domling, A.; Wang, W.; Wang, K. *Chem. Rev.* **2012**, *112*, 3083.  
<http://dx.doi.org/10.1021/cr100233r>
80. González-López, M.; Shaw, J. T. *Chem. Rev.* **2009**, *109*, 164.  
<http://dx.doi.org/10.1021/cr8002714>
81. Rotstein, B. H.; Zaretsky, S.; Rai, V.; Yudin, A. K. *Chem. Rev.* **2014**, *114*, 8323.  
<http://dx.doi.org/10.1021/cr400615v>

82. Sunderhaus, J. D.; Martin, S. F. *Chem. Eur. J.* **2009**, *15*, 1300.  
<http://dx.doi.org/10.1002/chem.200802140>
83. Guillena, G.; Ramon, D. J.; Yus, M. *Tetrahedron: Asymmetry* **2007**, *18*, 693.  
<http://dx.doi.org/10.1016/j.tetasy.2007.03.002>
84. Liu, H.; Dou, G.; Shi, D. J. *Comb. Chem.* **2010**, *12*, 292.  
<http://dx.doi.org/10.1021/cc900195t>
85. Roy, T.; Thangaraj, M.; Gonnade, R. G.; Biju, A. *Chem. Commun.* **2016**, *52*, 9044.  
<http://dx.doi.org/10.1039/c6cc00057f>
86. Parmar, B. D.; Sutariya, T. R.; Brahmabhatt, G. C.; Parmar, N. J.; Kant, R.; Gupta, V. K. *J* **2016**, *81*, 4955.  
<http://dx.doi.org/10.1021/acs.joc.6b00107>
87. Liu, X.-W.; Yao, Z.; Yang, J.; Chen, Z.-Y.; Liu, X.-L.; Zhao, Z.; Lu, Y.; Zhou, Y.; Cao, Y. *Tetrahedron* **2016**, *72*, 1364.  
<http://dx.doi.org/10.1016/j.tet.2016.01.029>
88. Liu, X.-L.; Yang, C.; Zhang, W.-H.; Zhou, G.; Ma, X.-T.; Lin, B.; Zhang, M.; Zhou, Y.; Feng, T.-T. *Tetrahedron Lett.* **2016**, *57*, 1385.  
<http://dx.doi.org/10.1016/j.tetlet.2016.02.074>
89. Sumesh, R. V.; Muthu, M.; Almansour, A. I.; Suresh Kumar, R.; Arumugam, N.; Athimoolam, S.; Jeya Yasmi Prabha, E. A.; Kumar, R. R. *ACS Comb. Sci.* **2016**, *18*, 262.  
<http://dx.doi.org/10.1021/acscombsci.6b00003>
90. Cores, Á.; Estévez, V.; Villacampa, M.; Menéndez, J. C. *RSC Adv.* **2016**, *6*, 39433.  
<http://dx.doi.org/10.1039/C6RA06317A>
91. Nayak, S.; K Mishra, S.; Bhakta, S.; Panda, P.; Baral, N.; Mohapatra, S.; S Purohit, C.; Satha, P. *Lett. Org. Chem.* **2016**, *13*, 11.  
<http://dx.doi.org/10.2174/1570178612666151030213735>
92. George, R. F.; Panda, S. S.; Shalaby, E. S. M.; Srouf, A. M.; Farag, I. S. A.; Girgis, A. S. *RSC Adv.* **2016**, *6*, 45434.  
<http://dx.doi.org/10.1039/C6RA07061B>
93. Uma Rani, G.; Vivek Kumar, S.; Bharkavi, C.; Menéndez, J. C.; Perumal, S. *ACS Comb. Sci.* **2016**, *18*, 337.  
<http://dx.doi.org/10.1021/acscombsci.6b00011>
94. Mathusalini, S.; Arasakumar, T.; Lakshmi, K.; Lin, C.-H.; Mohan, P. S.; Ramnath, M. G.; Thirugnanasampandan, R. *New J. Chem.* **2016**, *40*, 5164.  
<http://dx.doi.org/10.1039/c6nj00534a>
95. Hamama, W. S.; Hassanien, A. E.; El-Fedawy, M. G.; Zoorob, H. H. *J. Heterocycl. Chem.* **2017**, *54*, 859.  
<http://dx.doi.org/10.1002/jhet.2646>
96. Sankar, U.; Surya Kumar, C. V.; Subramanian, V.; Balasubramanian, K. K.; Mahalakshmi, S. *J. Org. Chem.* **2016**, *81*, 2340.  
<http://dx.doi.org/10.1021/acs.joc.5b02845>
97. Ramesh, P.; Rao, K. S.; Trivedi, R.; Kumar, B. S.; Prakasham, R.; Sridhar, B. *RSC Adv.* **2016**, *6*, 26546.  
<http://dx.doi.org/10.1039/C6RA00613B>
98. Shi, G.; He, X.; Shang, Y.; Xie, M. *RSC Adv.* **2016**, *6*, 10412.  
<http://dx.doi.org/10.1039/c5ra23860a>
99. Wang, Y.-M.; Zhang, H.-H.; Li, C.; Fan, T.; Shi, F. *Chem. Commun.* **2016**, *52*, 1804.  
<http://dx.doi.org/10.1039/C5CC07924A>

100. Safaei-Ghomi, J.; Zahedi, S. *Tetrahedron Lett.* **2016**, 57, 1071.  
<http://dx.doi.org/10.1016/j.tetlet.2016.01.073>
101. Preetam, A.; Nath, M. *Tetrahedron Lett.* **2016**, 57, 1502.  
<http://dx.doi.org/10.1016/j.tetlet.2016.02.079>
102. Rajeswari, M.; Kumari, S.; Khurana, J. M. *RSC Adv.* **2016**, 6, 9297.  
<http://dx.doi.org/10.1039/C5RA26093K>
103. Mali, P. R.; Rao, L. C.; Bangade, V. M.; Shirsat, P. K.; George, S. A.; Babu, N. J.; Meshram, H. M. *New J. Chem.* **2016**, 40, 2225.  
<http://dx.doi.org/10.1039/C5NJ02126J>
104. Kumari, S.; Singh, H.; Khurana, J. M. *Tetrahedron Lett.* **2016**, 57, 3081.  
<http://dx.doi.org/10.1016/j.tetlet.2014.11.046>
105. Maryamabadi, A.; Hasaninejad, A.; Nowrouzi, N.; Mohebbi, G.; Asghari, B. *Bioorg. Med. Chem.* **2016**, 24, 1408.  
<http://dx.doi.org/10.1016/j.bmc.2016.02.019>
106. Shakibaei, G. I.; Bazgir, A. *RSC Adv.* **2016**, 6, 22306.  
<http://dx.doi.org/10.1039/C6RA00869K>
107. Mohammadi Ziarani, G.; Aleali, F.; Lashgari, N.; Badiei, A. R. *Iran. J. Chem. Chem. Eng.* **2016**, 35, 17.
108. Mohammadi Ziarani, G.; Asadi, S.; Badiei, A. R.; Sharifi, A.; Amanlou, M. *Iran. J. Pharm. Res.* **2016**, 15, 55.
109. Mohammadi Ziarani, G.; Hassanzadeh, Z.; Gholamzadeh, P.; Soorki, A. A. *Rev. Roum. Chim.* **2016**, 61, 77.
110. Sagir, H.; Rai, P.; Tiwari, S.; Siddiqui, I. *J. Heterocycl. Chem.* **2017**, 54, 397.  
<http://dx.doi.org/10.1002/jhet.2596>
111. Kumari, S.; Rajeswari, M.; Khurana, J. M. *Synth. Commun.* **2016**, 46, 387.  
<http://dx.doi.org/10.1080/00397911.2016.1141427>
112. Nalini, G.; Jayachandramani, N.; Thanikachalam, V.; Jayabharath, J.; Manikandan, G.; Suresh, R. *Can. Chem. Trans.* **2016**, 4, 62.  
<http://dx.doi.org/10.13179/canchemtrans.2016.04.01.0248>
113. Kefayati, H.; Bazargard, S. J.; Vejdansafat, P.; Shariati, S.; Kohankar, A. M. *Dyes Pigm.* **2016**, 125, 309.  
<http://dx.doi.org/10.1016/j.dyepig.2015.10.034>
114. Shi, R.-G.; Yan, C.-G. *Chin. Chem. Lett.* **2016**, 27, 575.  
<http://dx.doi.org/10.1016/j.cclet.2016.02.016>
115. Niknam, K.; Khataminejad, M.; Zeyaei, F. *Tetrahedron Lett.* **2016**, 57, 361.  
<http://dx.doi.org/10.1016/j.tetlet.2015.12.034>
116. Keshavarz, M. *J. Iran. Chem. Soc.* **2016**, 13, 553.  
<http://dx.doi.org/10.1007/s13738-015-0765-y>
117. Ramadoss, H.; Saravanan, D.; Sudhan, S. P. N.; Sheik Mansoor, S. *Der Pharma Chemica* **2016**, 8, 94.
118. Molla, A.; Hussain, S. *RSC Adv.* **2016**, 6, 5491.  
<http://dx.doi.org/10.1039/C5RA21969H>
119. Garcia-Garcia, P.; Moreno, J. M.; Diaz, U.; Bruix, M.; Corma, A. *Nat. Commun.* **2016**, 7, 10835.  
<http://dx.doi.org/10.1038/ncomms10835>
120. Padvi, S. A.; Tayade, Y. A.; Wagh, Y. B.; Dalal, D. S. *Chin. Chem. Lett.* **2016**, 27, 714.  
<http://dx.doi.org/10.1016/j.cclet.2016.01.016>
121. Molla, A.; Hussain, S. *Synfacts* **2016**, 12, 0426.  
<http://dx.doi.org/10.1055/s-0035-1561789>

122. Rashidi, A.; Tavakoli, Z.; Tarak, Y.; Khodabakhshi, S.; Abbasabadi, M. K. *J. Chin. Chem. Soc.* **2016**, *63*, 399.  
<http://dx.doi.org/10.1002/jccs.201500508>
123. Elinson, M. N.; Ryzhkov, F. V.; Zaimovskaya, T. A.; Egorov, M. P. *Monatsh. Chem.* **2016**, *147*, 755.  
<http://dx.doi.org/10.1007/s00706-015-1617-2>
124. Baghernejad, M.; Khodabakhshi, S.; Tajik, S. *New J. Chem.* **2016**, *40*, 2704.  
<http://dx.doi.org/10.1039/C5NJ03027G>
125. Brahmachari, G.; Banerjee, B. *Asian J. Org. Chem.* **2016**, *5*, 271.  
<http://dx.doi.org/10.1002/ajoc.201500465>
126. Moosavi-Zare, A. R.; Zolfigol, M. A.; Noroozizadeh, E.; Moratab, R. S.; Zarei, M. *J. Mol. Catal. A: Chem.* **2016**, *420*, 246.  
<http://dx.doi.org/10.1016/j.molcata.2016.04.021>
127. Stucchi, M.; Lesma, G.; Meneghetti, F.; Rainoldi, G.; Sacchetti, A.; Silvani, A. *J. Org. Chem.* **2016**, *81*, 1877.  
<http://dx.doi.org/10.1021/acs.joc.5b02680>
128. Mishra, K.; Basavegowda, N.; Lee, Y. R. *RSC Adv.* **2016**, *6*, 27974.  
<http://dx.doi.org/10.1039/C6RA03883B>
129. Maloo, P.; Roy, T. K.; Sawant, D. M.; Pardasani, R. T.; Salunkhe, M. M. *RSC Adv.* **2016**, *6*, 41897.  
<http://dx.doi.org/10.1039/C6RA05322J>
130. Alizadeh, A.; Moafi, L. *Synlett* **2016**, *27*, 595.  
<http://dx.doi.org/10.1055/s-0035-1560905>
131. Zhang, Y.-L.; Li, Y.-F.; Wang, J.-W.; Yu, B.; Y.-K., S.; Liu, H.-M. *Steroids* **2016**, *109*, 22.  
<http://dx.doi.org/10.1016/j.steroids.2016.03.005>
132. Rajanarendar, E.; Thirupathaiah, K.; Ramakrishna, S.; Nagaraju, D.; Kishore, B. *J. Heterocycl. Chem.* **2017**, *54*, 889.  
<http://dx.doi.org/10.1002/jhet.2650>
133. Chandam, D. R.; Mulik, A. G.; Patil, D. R.; Patravale, A. P.; Kumbhar, D. R.; Deshmukh, M. B. *J. Mol. Liq.* **2016**, *219*, 573.  
<http://dx.doi.org/10.1016/j.molliq.2016.02.101>
134. Shaabani, A.; Hooshmand, S. E.; Tabatabaei, A. T. **2016**, *57*, 351.  
<http://dx.doi.org/10.1016/j.tetlet.2015.12.017>
135. Shrestha, R.; Sharma, K.; Lee, Y. R.; Wee, Y.-J. *Mol. Divers.* **2016**, *20*, 847.  
<http://dx.doi.org/10.1007/s11030-016-9670-2>
136. Alemi-Tameh, F.; Safaei-Ghomi, J.; Mahmoudi-Hashemi, M.; Teymuri, R. *Res. Chem. Intermed.* **2016**, *42*, 6391.  
<http://dx.doi.org/10.1007/s11164-016-2470-6>
137. Fu, Z.; Qian, K.; Li, S.; Shen, T.; Song, Q. *Tetrahedron Lett.* **2016**, *57*, 1104.  
<http://dx.doi.org/10.1016/j.tetlet.2016.01.089>
138. Min, L.; Pan, B.; Gu, Y. *Org. Lett.* **2016**, *18*, 364.  
<http://dx.doi.org/10.1021/acs.orglett.5b03287>
139. Zhan, G.; Shi, M. L.; He, Q.; Lin, W. J.; Ouyang, Q.; Du, W.; Chen, Y. C. *Angew. Chem., Int. Ed.* **2016**, *55*, 2147.  
<http://dx.doi.org/10.1002/anie.201510825>
140. He, Y.-H.; He, T.; Guo, J.-T.; Li, R.; Xiang, Y.; Yang, D.-C.; Guan, Z. *Catal. Sci. Tech.* **2016**, *6*, 2239.  
<http://dx.doi.org/10.1039/C5CY00987A>

141. Hegade, P. G.; Chinchkar, S. D.; Pore, D. M. *Monatsh. Chem.* **2016**, 147, 1243.  
<http://dx.doi.org/10.1007/s00706-015-1637-y>
142. Deshmukh, R.; S Thakur, A.; K Jha, A.; Kumar, P. *Cent. Nerv. Syst. Agents Med. Chem.* **2016**, 16, 29.  
<http://dx.doi.org/10.2174/1871524915666150623091716>
143. Shi, R.-G.; Wang, X.-H.; Liu, R.; Yan, C.-G. *Chem. Commun.* **2016**, 52, 6280.  
<http://dx.doi.org/10.1039/C6CC00525J>
144. Mondal, A.; Banerjee, B.; Bhaumik, A.; Mukhopadhyay, C. *Chem. Cat. Chem.* **2016**, 8, 1185.  
<http://dx.doi.org/10.1002/cctc.v8.6>

## Authors Biographies



**Ghodsi Mohammadi Ziarani** was born in Iran, in 1964. She received her B.Sc. degree in Chemistry from Teacher Training University, Tehran, Iran, in 1987, her M.Sc. degree in Organic Chemistry from the Teacher Training University, Tehran, Iran, under the supervision of Professor Jafar Asgarin and Professor Mohammad Ali Bigdeli in 1991 and her Ph.D. degree in asymmetric synthesis (Biotransformation) from Laval University, Quebec, Canada under the supervision of Professor Chenevert, in 2000. She is Full Professor in the Science faculty of Alzahra University. Her research interests include organic synthesis, heterocyclic synthesis, asymmetric synthesis, natural products synthesis, synthetic methodology and applications of nano-heterogeneous catalysts in multicomponent reactions.



**Razieh Moradi** was born in 1990 in Lorestan, Iran. She obtained her B.Sc. degree in Chemistry from the University of Lorestan (2012) and her M.Sc. degree in Organic Chemistry at Alzahra University under the supervision of Dr Ghodsi Mohammadi Ziarani. She is currently Ph.D. student in Organic Chemistry at Alzahra University under the supervision of Dr Ghodsi Mohammadi Ziarani. Her research field is on the synthesis of heterocyclic compounds based on isatin and application of nano-heterogeneous catalysts in organic synthesis and multicomponent reactions.



**Negar Lashgari** was born in 1985 in Tehran, Iran. She received her B.Sc. degree in Applied Chemistry from Teacher Training University, Tehran, Iran (2008) and her M.Sc. degree in Organic Chemistry at Alzahra University, Tehran, Iran (2011) under the supervision of Dr Ghodsi Mohammadi Ziarani. She is currently working towards her Ph.D. in Nano-Chemistry at University of Tehran under the supervision of Dr Alireza Badiei and Dr Ghodsi Mohammadi Ziarani. Her research field is synthesis and application of nano-heterogeneous catalysts in multicomponent reactions.